drugset / Trial / NCT00066092

Pegfilgrastim PBPC Mobilization Study

NCT00066092

Phase 2 Completed 41 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, multi-center study to assess the safety and effectiveness of using a single subcutaneous (under the skin) injection of pegfilgrastim or daily subcutaneous injections of Filgrastim to mobilize stem cells for autologous transplantation in patients with Hodgkin's or non-Hodgkin's lymphoma.

Timeline

Start
2003-04
Primary completion
2004-03
Completion
2004-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Pegfilgrastim Protein / enzyme biologic 6 mg Subcutaneous
Subject Pegfilgrastim Protein / enzyme biologic 12 mg Subcutaneous
Comparator filgrastim Protein / enzyme biologic Subcutaneous